Advanced search
Publication Cover
Modern Rheumatology Volume 31, 2021 - Issue 4
Journal homepage
510
Views
7
CrossRef citations to date
0
Altmetric
Connective tissue diseases and related disorders

Efficacy and safety of apremilast for 3 months in Behçet’s disease: A prospective observational study

Lisa Hiraharaa Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, JapanView further author information
,
Yohei Kirinoa Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9488-661XView further author information
ORCID Icon,
Yutaro Soejimaa Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, JapanView further author information
,
Mitsuhiro Takenob Nippon Medical School Musashi Kosugi Hospital, Department of Allergy and Rheumatology, Kawasaki, JapanView further author information
,
Kaoru Takase-Minegishia Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, JapanView further author information
,
Ryusuke Yoshimia Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, JapanView further author information
,
Masaki Takeuchic Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, JapanView further author information
,
Nobuhisa Mizukic Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, JapanView further author information
&
Hideaki Nakajimaa Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, JapanView further author information
 show all
Pages 856-861 | Received 02 Sep 2020, Accepted 24 Sep 2020, Published online: 16 Oct 2020

References

  • Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. N Engl J Med. 1999;341(17):1284–91. Epub 1999/10/21.
  • Kirino Y, Ideguchi H, Takeno M, Suda A, Higashitani K, Kunishita Y, et al. Continuous evolution of clinical phenotype in 578 Japanese patients with Behçet’s disease: a retrospective observational study. Arthritis Res Ther. 2016;18(1):217. Epub 2016/10/08.
  • Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Behçet disease: evolution of clinical manifestations. Medicine (Baltimore). 2011;90(2):125–32.
  • Naito M, Suzukamo Y, Wakai K, Azechi M, Kaneko F, Nakayama T, et al. One-year period prevalence of oral aphthous ulcers and oral health-related quality of life in patients with Behçet’s disease. Genetics Res Int. 2014;2014:930348.
  • Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Behcet’s syndrome. Annal Rheumat Dis. 2018;77:808–18.
  • Nakamura K, Iwata Y, Asai J, Kawakami T, Tsunemi Y, Takeuchi M, et al. Guidelines for the treatment of skin and mucosal lesions in Behçet’s disease: a secondary publication. J Dermatol. 2020;47(3):223–35.
  • Alibaz-Oner F, Mumcu G, Kubilay Z, Ozen G, Celik G, Karadeniz A, et al. Unmet need in Behcet’s disease: most patients in routine follow-up continue to have oral ulcers. Clin Rheumatol. 2014;33(12):1773–6.
  • Takeno M. Positioning of apremilast in treatment of Behçet’s disease. Mod Rheumatol. 2020;30(2):219–24.
  • Hatemi G, Mahr A, Ishigatsubo Y, Song YW, Takeno M, Kim D, et al. Trial of apremilast for oral ulcers in Behcet’s syndrome. N Engl J Med. 2019;381(20):1918–28.
  • Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14(2):119.
  • Kirino Y, Nakajima H. Clinical and genetic aspects of Behcet’s disease in Japan. Intern Med. 2019;58:1199–207.
  • Galan Sanchez JL, Eguren Michelena C, de la Cueva Dobao P, Apremilast for the treatment of oral aphthae in Behcet disease. Medicina clinica. 2019. Apremilast en el tratamiento de las aftas orales en la enfermedad de Behcet.
  • De Luca G, Cariddi A, Campochiaro C, Vanni D, Boffini N, Tomelleri A, et al. Efficacy and safety of apremilast for Behcet’s syndrome: a real-life single-centre Italian experience. Rheumatology (Oxford.). 2020;59(1):171–5.
  • Lopalco G, Venerito V, Leccese P, Emmi G, Cantarini L, Lascaro N, et al. Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet’s disease. Ann Rheum Dis. 2019;78(12):1736–7.
  • Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease. Lancet 1990;335(8697):1078–80.
  • The International Criteria for Behcet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014;28(3):338–47.
  • Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behcet’s disease activity index. Rheumatology (Oxford). 2004;43(1):73–8.
  • Fagni F, Bettiol A, Talarico R, Lopalco G, Silvestri E, Urban ML, et al. Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behcet’s phenotype: a multicentre study. Ann Rheum Dis. 2020;79(8):1098–104.
  • Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, Mat C, et al. Apremilast for Behcet’s syndrome–a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510–8.
  • Cabras M, Carrozzo M, Gambino A, Broccoletti R, Sciascia S, Baldovino S, et al. Value of colchicine as treatment for recurrent oral ulcers: a systematic review. J Oral Pathol Med. 2020;49(8):731–740.
  • Leccese P, Ozguler Y, Christensen R, Esatoglu SN, Bang D, Bodaghi B, et al. Management of skin, mucosa and joint involvement of Behçet’s syndrome: a systematic review for update of the EULAR recommendations for the management of Behçet’s syndrome. Semin Arthritis Rheum. 2019;48(4):752–62.
  • Hirohata S, Kikuchi H, Sawada T, Okada M, Takeno M, Kuwana M, et al. Recommendations for the management of Neuro-Behcet’s disease by the Japanese National Research Committee for Behcet’s disease. Intern Med 2020;59(19):2359–2367.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.